CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes
Ousama Rachid, Aisha Osman, Reza Abdi, Yousef Haik
Abstract
: Immunomodulation is one of the promising strategies for decelerating the progression of beta-cell destruction after the onset of T1D. It holds the advantage of specific immune modulation without systemic general immunosuppression. Preclinical and clinical studies have yielded promising data on the use of CTLA4-Ig in T1D. Variations in response to CTLA4-Ig might be partially explained by the existence of multiple T1D subtypes with varying baseline innate inflammatory/regulatory bias and the rate of C-peptide decline.
Topics & Concepts
AbataceptType 2 diabetesMedicineDrugInvestigational DrugsPharmacologyDiabetes mellitusInternal medicineClinical trialEndocrinologyLymphomaRituximabDiabetes and associated disordersDiabetes Management and ResearchPancreatic function and diabetes